市場調查報告書
商品編碼
1019743

醫藥品有效成分的CDMO(醫藥品製造開發受託)的全球市場:各產品,合成,藥物,各應用領域,工作流程,各地區的市場規模,佔有率及趨勢分析,各市場區隔預測(2021年∼2028年)

Active Pharmaceutical Ingredients CDMO Market Size, Share & Trends Analysis Report By Product (Highly Potent API, Antibody Drug Conjugate), By Synthesis, By Drugs, By Application, By Workflow, By Region, And Segment Forecasts, 2021 - 2028

出版日期: | 出版商: Grand View Research, Inc. | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球醫藥品有效成分CDMO(醫藥品製造開發受託)的市場規模在2021年∼2028年間預計將以6.7%的年複合成長率擴大,到2028年達到1,361億美元。

醫藥品研究開發的投資的增加,專利的有效期限,及學名藥和生物學的創新的需求的增加等是促進市場成長的主要原因。

由於小分子的數量不斷增加、活性藥物成分 (API) 的日益複雜以及節約成本的需要,製藥行業的外包服務正在迅速擴大。

本報告提供全球醫藥品有效成分的CDMO(醫藥品製造開發受託)市場相關調查分析,提供市場及產業預測,各市場區隔·各地區的預測,加上競爭情形相關的系統性資訊。

目錄

第1章 調查手法和範圍

第2章 摘要整理

第3章 有效成分CDMO市場:變數,趨勢,及範圍

  • 市場細分化和範圍
  • 市場動態
  • 滲透與成長預測的製圖
  • COVID-19對市場的影響
  • 主要的交易與策略性聯盟分析
  • 醫藥品有效成分的CDMO:市場分析工具

第4章 醫藥品有效成分的CDMO市場:產品市場區隔分析

  • 各產品市場佔有率分析,2020年及2028年
  • 傳統的有效成分
  • 非常強力的有效成分
  • 抗體藥物複合體
  • 其他

第5章 醫藥品有效成分的CDMO市場:合成市場區隔分析

  • 各合成市場佔有率分析,2020年及2028年
  • 合成
  • 生物科技

第6章 醫藥品有效成分CDMO市場:醫藥品市場區隔分析

  • 各類醫藥品市場佔有率分析,2020年及2028年
  • 非專利

第7章 應用市場區隔分析

  • 各應用領域市場佔有率分析,2020年及2028年
  • 腫瘤學
  • 荷爾蒙
  • 青光眼
  • 心血管
  • 糖尿病
  • 其他

第8章 醫藥品有效成分的CDMO市場:工作流程市場區隔分析

  • 各工作流程市場佔有率分析,2020年及2028年
  • 臨床
  • 商業

第9章 有效成分的CDMO市場:各地區分析

  • 地區市場佔有率分析,2020年及2028年
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東·非洲

第10章 企業簡介

  • Cambrex
  • ReciPharm
  • ThermoFisher Pantheon
  • Corden Pharma.
  • Samsung Biologics
  • Lonza
  • Catalent
  • Siegfried
  • Piramal Pharma Solutions
  • Boehringer Ingelheim
目錄
Product Code: GVR-4-68038-282-2

Active Pharmaceutical Ingredients CDMO Market Growth & Trends

The global active pharmaceutical ingredients CDMO market size is expected to reach USD 136.1 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 6.7% from 2021 to 2028. Increasing pharmaceutical R&D investment, patent expirations, and rise in demand for generic drugs and biologic innovation are the factors driving the market.

The growth of small molecules, rising Active Pharmaceutical Ingredient (API) complexity, and the need to reduce costs are factors contributing to the rapid expansion of outsourcing services in the pharmaceutical sector. Only a few companies have achieved global reach and scale in the Contract Development and Manufacturing Organization (CDMO) sector, which is still fragmented. Besides, many companies are providing one-stop-shop solutions as an integrated source of APIs and formulations.

However, due to the COVID-19 pandemic, governments worldwide have opted to boycott APIs made in China. Due to government-imposed lockdown limitations in China, 44 firms were declared non-operational during the pandemic. As a consequence, various countries have launched programs to develop their own APIs, and countries across the EU have re-evaluated their healthcare models in order to combat the virus and ensure a steady supply of APIs.

COVID-19 has placed unprecedented expectations on API makers, as evidenced by the substantial increase in demand for medications required to manage critically ill patients on mechanical ventilation. As a result, the sudden need to rapidly increase production has emphasized the need for adaptability for API CDMOs in maintaining drug supply, with some companies proving better able to withstand the pressures of quick scale up than others.

Active Pharmaceutical Ingredients CDMO Market Report Highlights

The traditional active pharmaceutical ingredient dominated the market and accounted for the largest revenue share of 40.5% in 2020

The innovative drugs segment held 74.6% of the revenue share in 2020. This is largely attributed due to increasing FDA approvals for new molecular entities, and the increased focus on R&D by innovator API companies

The oncology segment dominated the market and accounted for the largest revenue share of 35.1% in 2020. This is due to the increasing demand for highly active APIs for cancer therapy

In Asia Pacific, the market is expected to register the fastest growth rate of 8.9% over the forecast period. Due to the extreme rising number of pharmaceutical companies and contract manufacturing organizations in developing countries like India and China, Asia Pacific is likely to overtake Europe and North America in the near future

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation & Scope
    • 1.1.1 Estimates And Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database
    • 1.3.2 GVR's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
    • 1.3.5 Details Of Primary Research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Region Wise Market Calculation
    • 1.6.1 Region Wise Market: Base Estimates
    • 1.6.2 Global Market: CAGR Calculation
  • 1.7 List of Secondary Sources
  • 1.8 Objectives
    • 1.8.1 Objective - 1: Understanding market dynamics
    • 1.8.2 Objective - 2: Understanding market estimates and forecasts
    • 1.8.3 Objective - 3: Understanding attributes such as strategy framework and competitor categorization
    • 1.8.4 Objective - 4: Understanding the key service and application scopes to conclude on the market size.

Chapter 2 Executive Summary

  • 2.1 Market Outlook

Chapter 3 Active Pharmaceutical Ingredient CDMO Market: Variables, Trends, & Scope

  • 3.1 Market Segmentation and Scope
  • 3.2 Market Dynamics
    • 3.2.1 Market Driver Analysis
      • 3.2.1.1 Increasing pharmaceutical R&D investment
      • 3.2.1.2 Rising demand for generic drugs
      • 3.2.1.3 Patent expiration
      • 3.2.1.4 Expanding consumption of biopharmaceuticals
    • 3.2.2 Market Restraint Analysis
      • 3.2.2.1 Stringent government regulations
  • 3.3 Penetration & Growth Prospect Mapping
  • 3.4 COVID-19 Impact on the Market
  • 3.5 Major Deals and Strategic Alliances Analysis
  • 3.6 Active Pharmaceutical Ingredient CDMO: Market Analysis Tools
    • 3.6.1 Industry Analysis - Porter's
    • 3.6.2 PESTEL Analysis

Chapter 4 Active Pharmaceutical Ingredient CDMO Market: Product Segment Analysis

  • 4.1 Active Pharmaceutical Ingredient CDMO Market: Product Market Share Analysis, 2020 & 2028
  • 4.2 Traditional Active Pharmaceutical Ingredient
    • 4.2.1 Traditional Active Pharmaceutical Ingredient Market, 2016 - 2028 (USD Million)
  • 4.3 Highly Potent Active Pharmaceutical Ingredient
    • 4.3.1 Highly Potent Active Pharmaceutical Ingredient Market, 2016 - 2028 (USD Million)
  • 4.4 Antibody Drug Conjugate
    • 4.4.1 Antibody Drug Conjugate Market, 2016 - 2028 (USD Million)
  • 4.5 Others
    • 4.5.1 Others, 2016 - 2028 (USD Million)

Chapter 5 Active Pharmaceutical Ingredient CDMO Market: Synthesis Segment Analysis

  • 5.1 Active Pharmaceutical Ingredient CDMO Market: Synthesis Market Share Analysis, 2020 & 2028
  • 5.2 Synthetic
    • 5.2.1 Synthetic Active Pharmaceutical Ingredient CDMO market, 2016 - 2028 (USD Million)
  • 5.3 Biotech
    • 5.3.1 Biotech Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)

Chapter 6 Active Pharmaceutical Ingredient CDMO Market: Drug Segment Analysis

  • 6.1 Active Pharmaceutical Ingredient CDMO Market: Drug Market Share Analysis, 2020 & 2028
  • 6.2 Innovative
    • 6.2.1 Innovative active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
  • 6.3 Generics
    • 6.3.1 Generics Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)

Chapter 7 Active Pharmaceutical Ingredient CDMO Market: Application Segment Analysis

  • 7.1 Active Pharmaceutical Ingredient CDMO Market: Application Market Share Analysis, 2020 & 2028
  • 7.2 Oncology
    • 7.2.1 Oncology Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
  • 7.3 Hormonal
    • 7.3.1. Hormonal Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
  • 7.4 Glaucoma
    • 7.4.1. Glaucoma Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
  • 7.5 Cardiovascular
    • 7.5.1. Cardiovascular Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
  • 7.6 Diabetes
    • 7.6.1. Diabetes Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
  • 7.7 Others
    • 7.7.1. Others Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)

Chapter 8 Active Pharmaceutical Ingredient CDMO Market: Work Flow Segment Analysis

  • 8.1 Active Pharmaceutical Ingredient CDMO Market: Workflow Market Share Analysis, 2020 & 2028
  • 8.2 Clinical
    • 8.2.1 Clinical Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
  • 8.3 Commerical
    • 8.3.1 Commerical Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)

Chapter 9 Active Pharmaceutical Ingredient CDMO Market: Regional Analysis

  • 9.1 Active Pharmaceutical Ingredient CDMO Market: Regional Market Share Analysis, 2020 & 2028
  • 9.2 North America
    • 9.2.1 North America Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
    • 9.2.2 U.S.
      • 9.2.2.1 U.S. Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
    • 9.2.3 Canada
      • 9.2.3.1 Canada Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
  • 9.3 Europe
    • 9.3.1 Europe Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
    • 9.3.2 U.K.
      • 9.3.2.1 U.K. Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
    • 9.3.3 Germany
      • 9.3.3.1 Germany Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
    • 9.3.4 France
      • 9.3.4.1 France Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
    • 9.3.5 Italy
      • 9.3.5.1 Italy Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
    • 9.3.6 Spain
      • 9.3.6.1 Spain Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
  • 9.4 Asia Pacific
    • 9.4.1 Asia Pacific Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
    • 9.4.2 Japan
      • 9.4.2.1 Japan Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
    • 9.4.3 China
      • 9.4.3.1 China Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
    • 9.4.4 India
      • 9.4.4.1 India Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
    • 9.4.5 Australia
      • 9.4.5.1 Australia Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
    • 9.4.6 South Korea
      • 9.4.6.1 South Korea Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
  • 9.5 Latin America
    • 9.5.1 Latin America Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
    • 9.5.2 Brazil
      • 9.5.2.1 Brazil Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
    • 9.5.3 Mexico
      • 9.5.3.1 Mexico Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
    • 9.5.4 Argentina
      • 9.5.4.1 Argentina Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
    • 9.5.5 Colombia
      • 9.5.5.1 Colombia Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
    • 9.5.6 Chile
      • 9.5.6.1 Chile Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
  • 9.6 MEA
    • 9.6.1 MEA Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
    • 9.6.2 South Africa
      • 9.6.2.1 South Africa Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
    • 9.6.3 Saudi Arabia
      • 9.6.3.1 Saudi Arabia Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
    • 9.6.4 UAE
      • 9.6.4.1 UAE Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)

Chapter 10 Company Profiles

  • 10.1 Cambrex
    • 10.1.1 Company Overview
    • 10.1.2 Service Benchmarking
    • 10.1.3 Financial Performance
    • 10.1.4 Strategic Initiatives
  • 10.2 ReciPharm
    • 10.2.1 Company Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Service Benchmarking
    • 10.2.4 Strategic Initiatives
  • 10.3 ThermoFisher Pantheon
    • 10.3.1 Company Overview
    • 10.3.2 Service Benchmarking
    • 10.3.3 Strategic Initiatives
  • 10.4 Corden Pharma.
    • 10.4.1 Company Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Service Benchmarking
  • 10.5 Samsung Biologics
    • 10.5.1 Company Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Service Benchmarking
  • 10.6 Lonza
    • 10.6.1 Company Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Service Benchmarking
  • 10.7 Catalent
    • 10.7.1 Company Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Service Benchmarking
    • 10.7.4 Strategic Initiatives
  • 10.8 Siegfried
    • 10.8.1 Company Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Service Benchmarking
  • 10.9 Piramal Pharma Solutions
    • 10.9.1 Company Overview
    • 10.9.2 Financial Performance
    • 10.9.3 Service Benchmarking
    • 10.9.4 Strategic Initiatives
  • 10.10 Boehringer Ingelheim
    • 10.10.1 Company Overview
    • 10.10.2 Financial Performance
    • 10.10.3 Service Benchmarking
    • 10.10.4 Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Active Pharmaceutical Ingredient CDMO Market, by Region, 2016 - 2028 (USD Million)
  • Table 4 Global Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
  • Table 5 Global Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
  • Table 6 Global Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
  • Table 7 Global Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
  • Table 8 Global Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
  • Table 9 North America Active Pharmaceutical Ingredient CDMO Market, by Country, 2016 - 2028 (USD Million)
  • Table 10 North America Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
  • Table 11 North America Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
  • Table 12 North America Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
  • Table 13 North America Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
  • Table 14 North America Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
  • Table 15 U.S. Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
  • Table 16 U.S. Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
  • Table 17 U.S. Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
  • Table 18 U.S. Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
  • Table 19 U.S. Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
  • Table 20 Canada Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
  • Table 21 Canada Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
  • Table 22 Canada Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
  • Table 23 Canada Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
  • Table 24 Canada Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
  • Table 25 Europe Active Pharmaceutical Ingredient CDMO Market, by Country, 2016 - 2028 (USD Million)
  • Table 26 Europe Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
  • Table 27 Europe Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
  • Table 28 Europe Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
  • Table 29 Europe Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
  • Table 30 Europe Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
  • Table 31 U.K. Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
  • Table 32 U.K. Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
  • Table 33 U.K. Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
  • Table 34 U.K. Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
  • Table 35 U.K. Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
  • Table 36 Germany Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
  • Table 37 Germany Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
  • Table 38 Germany Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
  • Table 39 Germany Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
  • Table 40 Germany Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
  • Table 41 France Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
  • Table 42 France Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
  • Table 43 France Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
  • Table 44 France Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
  • Table 45 France Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
  • Table 46 Italy Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
  • Table 47 Italy Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
  • Table 48 Italy Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
  • Table 49 Italy Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
  • Table 50 Italy Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
  • Table 51 Spain Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
  • Table 52 Spain Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
  • Table 53 Spain Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
  • Table 54 Spain Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
  • Table 55 Spain Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
  • Table 56 Asia Pacific Active Pharmaceutical Ingredient CDMO Market, by Country, 2016 - 2028 (USD Million)
  • Table 57 Asia Pacific Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
  • Table 58 Asia Pacific Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
  • Table 59 Asia Pacific Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
  • Table 60 Asia Pacific Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
  • Table 61 Asia Pacific Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
  • Table 62 India Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
  • Table 63 India Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
  • Table 64 India Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
  • Table 65 India Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
  • Table 66 India Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
  • Table 67 Japan Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
  • Table 68 Japan Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
  • Table 69 Japan Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
  • Table 70 Japan Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
  • Table 71 Japan Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
  • Table 72 China Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
  • Table 73 China Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
  • Table 74 China Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
  • Table 75 China Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
  • Table 76 China Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
  • Table 77 Australia Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
  • Table 78 Australia Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
  • Table 79 Australia Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
  • Table 80 Australia Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
  • Table 81 Australia Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
  • Table 82 South Korea Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
  • Table 83 South Korea Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
  • Table 84 South Korea Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
  • Table 85 South Korea Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
  • Table 86 South Korea Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
  • Table 87 Latin America Active Pharmaceutical Ingredient CDMO Market, by Country, 2016 - 2028 (USD Million)
  • Table 88 Latin America Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
  • Table 89 Latin America Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
  • Table 90 Latin America Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
  • Table 91 Latin America Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
  • Table 92 Latin America Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
  • Table 93 Brazil Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
  • Table 94 Brazil Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
  • Table 95 Brazil Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
  • Table 96 Brazil Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
  • Table 97 Brazil Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
  • Table 98 Mexico Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
  • Table 99 Mexico Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
  • Table 100 Mexico Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
  • Table 101 Mexico Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
  • Table 102 Mexico Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
  • Table 103 Argentina Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
  • Table 104 Argentina Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
  • Table 105 Argentina Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
  • Table 106 Argentina Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
  • Table 107 Argentina Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
  • Table 108 Colombia Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
  • Table 109 Colombia Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
  • Table 110 Colombia Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
  • Table 111 Colombia Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
  • Table 112 Colombia Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
  • Table 113 Chile Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
  • Table 114 Chile Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
  • Table 115 Chile Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
  • Table 116 Chile Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
  • Table 117 Chile Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
  • Table 118 MEA Active Pharmaceutical Ingredient CDMO Market, by Country, 2016 - 2028 (USD Million)
  • Table 119 MEA Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
  • Table 120 MEA Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
  • Table 121 MEA Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
  • Table 122 MEA Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
  • Table 123 MEA Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
  • Table 124 South Africa Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
  • Table 125 South Africa Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
  • Table 126 South Africa Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
  • Table 127 South Africa Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
  • Table 128 South Africa Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
  • Table 129 South Arabia Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
  • Table 130 South Arabia Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
  • Table 131 South Arabia Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
  • Table 132 South Arabia Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
  • Table 133 South Arabia Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
  • Table 134 UAE Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
  • Table 135 UAE Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
  • Table 136 UAE Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
  • Table 137 UAE Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
  • Table 138 UAE Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Secondary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Active Pharmaceutical Ingredients CDMO market snapshot (2020)
  • Fig. 9 Active Pharmaceutical Ingredients CDMO market segmentation
  • Fig. 10 Market driver relevance analysis (Current & future impact)
  • Fig. 11 Market restraint relevance analysis (Current & future impact)
  • Fig. 12 Penetration & growth prospect mapping
  • Fig. 13 Porter's five forces analysis
  • Fig. 14 PESTEL analysis
  • Fig. 15 Active Pharmaceutical Ingredients CDMO market Product outlook: Segment dashboard
  • Fig. 16 Active Pharmaceutical Ingredients CDMO market: Product movement analysis
  • Fig. 17 Traditional Active Pharmaceutical Ingredient market, 2016 - 2028 (USD Million)
  • Fig. 18 Highly Potent Active Pharmaceutical Ingredient market, 2016 - 2028 (USD Million)
  • Fig. 19 Antibody Drug Conjugate market, 2016 - 2028 (USD Million)
  • Fig. 20 Others market, 2016 - 2028 (USD Million)
  • Fig. 21 Active Pharmaceutical Ingredients CDMO market Synthesis outlook: Segment dashboard
  • Fig. 22 Active Pharmaceutical Ingredients CDMO market: Synthesis movement analysis
  • Fig. 23 Synthetic based Active Pharmaceutical Ingredients CDMO market, 2016 - 2028 (USD Million)
  • Fig. 24 Biotech based Active Pharmaceutical Ingredients CDMO market, 2016 - 2028 (USD Million)
  • Fig. 25 Active Pharmaceutical Ingredients CDMO market Drug outlook: Segment dashboard
  • Fig. 26 Active Pharmaceutical Ingredients CDMO market: Drug movement analysis
  • Fig. 27 Innovative based Active Pharmaceutical Ingredients CDMO market, 2016 - 2028 (USD Million)
  • Fig. 28 Generics based Active Pharmaceutical Ingredients CDMO market, 2016 - 2028 (USD Million)
  • Fig. 29 Active Pharmaceutical Ingredients CDMO market Application outlook: Segment dashboard
  • Fig. 30 Active Pharmaceutical Ingredients CDMO market: Application movement analysis
  • Fig. 31 Oncology market, 2016 - 2028 (USD Million)
  • Fig. 32 Hormonal market, 2016 - 2028 (USD Million)
  • Fig. 33 Glaucoma market, 2016 - 2028 (USD Million)
  • Fig. 34 Cardiovascular market, 2016 - 2028 (USD Million)
  • Fig. 35 Diabetes market, 2016 - 2028 (USD Million)
  • Fig. 36 Others market, 2016 - 2028 (USD Million)
  • Fig. 37 Active Pharmaceutical Ingredients CDMO market Workflow outlook: Segment dashboard
  • Fig. 38 Active Pharmaceutical Ingredients CDMO market: Workflow movement analysis
  • Fig. 39 Clinical market, 2016 - 2028 (USD Million)
  • Fig. 40 Commercial market, 2016 - 2028 (USD Million)
  • Fig. 41 Regional market: Key takeaways
  • Fig. 42 Regional outlook, 2020 & 2028
  • Fig. 43 North America market, 2016 - 2028 (USD Million)
  • Fig. 44 U.S. market, 2016 - 2028 (USD Million)
  • Fig. 45 Canada market, 2016 - 2028 (USD Million)
  • Fig. 46 Europe market, 2016 - 2028 (USD Million)
  • Fig. 47 U.K. market, 2016 - 2028 (USD Million)
  • Fig. 48 Germany market, 2016 - 2028 (USD Million)
  • Fig. 49 France market, 2016 - 2028 (USD Million)
  • Fig. 50 Italy market, 2016 - 2028 (USD Million)
  • Fig. 51 Spain market, 2016 - 2028 (USD Million)
  • Fig. 52 Asia Pacific market, 2016 - 2028 (USD Million)
  • Fig. 53 Japan market, 2016 - 2028 (USD Million)
  • Fig. 54 China market, 2016 - 2028 (USD Million)
  • Fig. 55 India market, 2016 - 2028 (USD Million)
  • Fig. 56 Australia market, 2016 - 2028 (USD Million)
  • Fig. 57 South Korea market, 2016 - 2028 (USD Million)
  • Fig. 58 Latin America market, 2016 - 2028 (USD Million)
  • Fig. 59 Brazil market, 2016 - 2028 (USD Million)
  • Fig. 60 Mexico market, 2016 - 2028 (USD Million)
  • Fig. 61 Argentina market, 2016 - 2028 (USD Million)
  • Fig. 62 Colombia market, 2016 - 2028 (USD Million)
  • Fig. 63 Chile market, 2016 - 2028 (USD Million)
  • Fig. 64 MEA market, 2016 - 2028 (USD Million)
  • Fig. 65 South Africa market, 2016 - 2028 (USD Million)
  • Fig. 66 Saudi Arabia market, 2016 - 2028 (USD Million)
  • Fig. 67 UAE market, 2016 - 2028 (USD Million)